Exagen logo
Exagen
XGN | NASDAQ
Chart Builder DCF Calculator
$3.77
-$0.36 (-8.72%)
At close: Nov 16, 2026, 4:00 PM ET
$3.80
+$0.03 (+0.80%)
After-hours: Nov 16, 2026, 7:30 PM ET

Exagen Company Profile

Company profile explained

Company Profile

Exagen Inc. develops and commercializes diagnostic testing solutions, leveraging its proprietary cell-bound complement activation products (CB-CAPs) technology under the AVISE brand throughout the United States. The company's mission is to equip rheumatologists with advanced tools for the precise diagnosis, prognosis, and ongoing management of autoimmune and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its flagship product, AVISE CTD, aids in distinguishing between various connective tissue diseases (CTDs) and other conditions with overlapping symptoms in symptomatic patients. The company's product portfolio includes AVISE Lupus, which assesses complement system activation by measuring B-cell C4d and erythrocyte-bound C4d in blood. AVISE APS offers a comprehensive panel of autoantibody tests for the diagnosis and management of Antiphospholipid Syndrome (APS). For SLE patients, AVISE SLE Prognostic provides an autoantibody panel to evaluate the potential for kidney, brain, and cardiovascular complications. Additionally, AVISE Vasculitis AAV utilizes a testing panel of individual analytes to assist physicians in the assessment and monitoring of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, while AVISE Anti-CarP helps identify RA patients prone to severe disease, and AVISE PC4d measures platelet-bound C4d. Further offerings include AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, designed to monitor hydroxychloroquine levels. Exagen also holds a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to advance the development of novel patented biomarkers. Incorporated in 2002, the company was formerly known as Exagen Diagnostics, Inc. before rebranding to Exagen Inc. in January 2019. Its headquarters are located in Vista, California.

Key Executives

Name Position
John Aballi Chief Executive Officer, President & Director
Jeffrey G. Black Chief Financial Officer & Corporate Secretary
Michael Mahler Chief Scientific Officer
Prashanti Reddy Chief Medical Officer
Tina Jacobsen Vice President of Investor Relations
Tina S. Nova Executive Chairman of the Board of Directors

Latest SEC Filings

Date Type Title
Oct 20, 2026 4 Filing
Oct 19, 2026 4 Filing
Oct 19, 2026 3 Filing
Sep 02, 2026 4 Filing
Aug 24, 2026 4/A [Amend] Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jun 22, 2026 4 Filing
View All SEC Filings ➞
Exagen
Exagen logo
Country United States
IPO Date Sep 19, 2019
Industry Medical - Diagnostics & Research
Sector Healthcare
Employees 216
CEO John Aballi

Contact Details

1261 Liberty Way Vista, California 92081 United States

Stock Details

Ticker Symbol XGN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001274737
CUSIP Number 30068X103
ISIN Number US30068X1037
SIC Code 8071

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.